What is the 13F Pro Quality Score for ASRT?

13F Pro ranks Assertio Holdings, Inc. (ASRT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ASRT's current score at https://13fpro.ai/research/ASRT (free sign-up required for the full ranking).

Where does 13F Pro source ASRT data?

All Assertio Holdings, Inc. fundamentals and ownership data come directly from SEC EDGAR. Assertio Holdings, Inc. files with the SEC under CIK 1808665. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ASRT in?

Assertio Holdings, Inc. (ASRT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ASRT research updated on 13F Pro?

ASRT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Assertio Holdings, Inc.(ASRT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1808665 ASRT stock profile & AI dashboard →

13F Pro Quality Score

27.2/100

Rank #2,471 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

10.2/100

Profitability

14.1/100

Balance Sheet

14.5/100

Earnings Quality

30.0/100

Free Cash Flow

61.0/100

Institutional Flow

99.9/100

Revenue Scale

18.9/100

Dilution Risk

34.4/100

ASRT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Assertio Holdings, Inc. (ASRT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ASRT at 27.2/100 on a 32-signal composite quality model, placing it at rank #2,471 of 2,879 stocks — the bottom half of the AI-ranked universe. ASRT scores in the top quartile across institutional flow (99.9). Areas of concern include revenue growth (10.2) and profitability (14.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 34.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Assertio Holdings, Inc. reports quarterly revenue of $9.9M, net income of $-18.9M, free cash flow of $8.6M. Top institutional holders of ASRT by reported 13-F value include Context Capital Management,, Nantahala Capital Management,, OAKTREE CAPITAL MANAGEMENT, based on the most recent SEC filings. ASRT trades on the Nasdaq exchange and files with the SEC under CIK 1808665. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ASRT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Assertio Holdings, Inc. directly from SEC EDGAR. Assertio Holdings, Inc.'s 13F Pro composite quality score has ranged between 13 and 65 since 2021, currently 27.2 — a declining long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about Assertio Holdings, Inc.

Quirks, history, and lore behind ASRT — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · small-cap · listed on Nasdaq · focused on non-opioid pain management and related conditions.
2
The Numbers
Annual revenue in the range of roughly $50–60 million — not a blockbuster, but it keeps the lights on with a lean, commercial-stage operation and a tight product portfolio.
3
The History
The company rebranded and restructured over the years, shedding its earlier identity to sharpen focus on pain and inflammation — a pivot that came with a new name and ticker to match its refreshed mission.
4
The Secret
It competes in a crowded pain-drug market by owning commercial rights to established prescription products rather than betting the farm on risky early-stage R&D — steady, if unglamorous.
5
The Lore
One of its key products, Indocin, is an old-school indomethacin brand that has been treating pain and acute gout flares since well before most of its current shareholders were born.
6
The Giveaway
Its ticker spells out ASRT — short for "assert" — and its full name is a mouthful that essentially means "Holdings of Assertiveness." The pain-focused pharma formerly known as Depomed found its voice.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$9.9M

Net Income

Q1 2026

$-18.9M

Free Cash Flow

Q1 2026

$8.6M

D/E Ratio

Q1 2026

0.52

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-5.0% YoY

$118.7MFY 2025

FY22 $156.2MFY23 $152.1MFY24 $125.0MFY25 $118.7M

Net Income

-40.7% YoY

$-30.4MFY 2025

FY22 $109.6MFY23 $-331.9MFY24 $-21.6MFY25 $-30.4M

Operating Income

+12.0% YoY

$-21.5MFY 2025

FY22 $39.4MFY23 $-243.5MFY24 $-24.5MFY25 $-21.5M

EPS (Diluted)

-39.4% YoY

$-4.74FY 2025

FY22 $2.03FY23 $-4.67FY24 $-3.40FY25 $-4.74

Total Assets

-6.2% YoY

$267.0MFY 2025

FY22 $413.9MFY23 $286.4MFY24 $284.7MFY25 $267.0M

Total Debt

+0.8% YoY

$39.1MFY 2025

FY22 $67.3MFY23 $38.5MFY24 $38.8MFY25 $39.1M

Op. Cash Flow

-206.7% YoY

$-28.2MFY 2025

FY22 $78.6MFY23 $49.6MFY24 $26.4MFY25 $-28.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$118.7M -5.0%	$125.0M -17.8%	$152.1M -2.7%	$156.2M +40.7%	$111.0M +4.5%	$106.3M
Net Income	$-30.4M -40.7%	$-21.6M +93.5%	$-331.9M -402.8%	$109.6M +8657.8%	$-1.3M +95.4%	$-28.1M
Operating Income	$-21.5M +12.0%	$-24.5M +89.9%	$-243.5M -718.0%	$39.4M +318.1%	$9.4M +111.5%	$-82.2M
EPS (Diluted)	$-4.74 -39.4%	$-3.40 +27.2%	$-4.67 -330.0%	$2.03 +6866.7%	$-0.03 +97.2%	$-1.07
Total Assets	$267.0M -6.2%	$284.7M -0.6%	$286.4M -30.8%	$413.9M +26.8%	$326.5M +7.7%	$303.3M
Total Debt	$39.1M +0.8%	$38.8M +0.8%	$38.5M -42.8%	$67.3M -31.2%	$97.8M -9.4%	$108.0M
Operating Cash Flow	$-28.2M -206.7%	$26.4M -46.8%	$49.6M -36.9%	$78.6M +1323.1%	$5.5M +108.4%	$-65.6M

Get alerted when ASRT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Assertio Holdings, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ASRT

Context Capital Management, LLC
$24.3M24,230,000 sh
Nantahala Capital Management, LLC
$13.2M692,335 sh
OAKTREE CAPITAL MANAGEMENT LP
$7.0M212,875,428 sh
VANGUARD CAPITAL MANAGEMENT LLC
$5.1M268,952 sh
Opaleye Management Inc.
$5.1M265,707 sh
RENAISSANCE TECHNOLOGIES LLC
$4.4M228,599 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$2.9M149,900 sh
Chicago Capital Management, LLC
$2.6M2,750 sh
EDGEWOOD MANAGEMENT LLC
$2.0M107,517 sh
BlackRock, Inc.
$1.7M90,035 sh

Fund	Value	Shares
Context Capital Management, LLC	$24.3M	24,230,000
Nantahala Capital Management, LLC	$13.2M	692,335
OAKTREE CAPITAL MANAGEMENT LP	$7.0M	212,875,428
VANGUARD CAPITAL MANAGEMENT LLC	$5.1M	268,952
Opaleye Management Inc.	$5.1M	265,707
RENAISSANCE TECHNOLOGIES LLC	$4.4M	228,599
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$2.9M	149,900
Chicago Capital Management, LLC	$2.6M	2,750
EDGEWOOD MANAGEMENT LLC	$2.0M	107,517
BlackRock, Inc.	$1.7M	90,035

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ASRT on your watchlist

Track score changes the day Assertio Holdings, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ASRT a good stock to buy?

13F Pro's AI-powered analysis of Assertio Holdings, Inc. (ASRT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ASRT are available on the ASRT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ASRT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ASRT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Assertio Holdings, Inc.'s investment landscape.